EC
BMRN icon

Elequin Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Elequin Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1
Closed -$56 – 729
2026
Q1 		$56 Sell
1
-3
-75% -$175 ﹤0.01% 616
2025
Q4 		$238 Buy
+4
New +$218 ﹤0.01% 396
2025
Q1 		– Sell
-25
Closed -$1.64K – 363
2024
Q4 		$1.64K Sell
25
-4
-14% -$268 ﹤0.01% 452
2024
Q3 		$2.04K Buy
+29
New +$2.42K ﹤0.01% 323
2024
Q2 		– Sell
-42
Closed -$3.67K – 211
2024
Q1 		$3.67K Buy
+42
New +$3.76K ﹤0.01% 166
2023
Q3 		– Sell
-99
Closed -$8.58K – 424
2023
Q2 		$8.58K Buy
+99
New +$9.32K ﹤0.01% 318
2022
Q4 		– Sell
-87
Closed -$7K – 634
2022
Q3 		$7K Sell
87
-152
-64% -$13.5K ﹤0.01% 296
2022
Q2 		$20K Buy
239
+50
+26% +$3.98K ﹤0.01% 192
2022
Q1 		$15K Buy
+189
New +$15.8K ﹤0.01% 144

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Elequin Capital's BMRN Position: Q2 2026 in Review

Elequin Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 1 share — an estimated $56 sold.

Elequin Capital first reported a position in BMRN in Q1 2022 and held it in 9 quarters. The position peaked at $20K in Q2 2022. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Elequin Capital reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Elequin Capital sold 1 BioMarin Pharmaceuticals share in Q2 2026, an estimated $56.
  • Elequin Capital first reported a position in BioMarin Pharmaceuticals in Q1 2022 and held it in 9 quarters.
  • Elequin Capital's BioMarin Pharmaceuticals position peaked at $20K in Q2 2022.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Elequin Capital's 13F filing for Q2 2026, filed 13 Aug 2026.